Pharmacokinetics of iopentol in patients with chronic renal failure. 1992

M G Svaland, and F Kolmannskog, and P E Lillevold, and K P Nordal, and L Ressem, and K J Berg
Research and Development Division, Nycomed AS, Oslo, Norway.

Iopentol 350 mg I/ml was injected in doses of 265 to 533 mg I/kg b.w. (mean 417 mg I/kg b.w.) in 10 patients with advanced nondiabetic chronic renal failure (S-creatinine 672 +/- 259 mumol/l (mean +/- SD)). Urine (10 patients) and feces (7 patients) were collected at 24 h intervals for 5 days after the injection. The elimination of iopentol was delayed. Five days after injection a mean of 54% (range 35-79%) of the dose was recovered in urine, and 11% (0-20%) in feces. Mean elimination half-life was 28.4 h, about 14 times the half-life found in healthy volunteers. The apparent volume of distribution was 0.27 l/kg b.w., indicating distribution only to extracellular fluid. Using renal iopentol clearance as reference value, GFR was overestimated by 40 to 60% with iopentol total clearance, showing extrarenal elimination of iopentol. The difference was most pronounced in patients with low GFR. In conclusion, this study shows an extrarenal elimination of iopentol and demonstrates a substantial increase in the fecal elimination in patients with severe renal failure.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003287 Contrast Media Substances used to allow enhanced visualization of tissues. Radiopaque Media,Contrast Agent,Contrast Agents,Contrast Material,Contrast Materials,Radiocontrast Agent,Radiocontrast Agents,Radiocontrast Media,Agent, Contrast,Agent, Radiocontrast,Agents, Contrast,Agents, Radiocontrast,Material, Contrast,Materials, Contrast,Media, Contrast,Media, Radiocontrast,Media, Radiopaque
D005243 Feces Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014283 Triiodobenzoic Acids Triiodo-substituted derivatives of BENZOIC ACID. Triiodobenzoic Acid,Acid, Triiodobenzoic,Acids, Triiodobenzoic

Related Publications

M G Svaland, and F Kolmannskog, and P E Lillevold, and K P Nordal, and L Ressem, and K J Berg
April 1987, Clinical pharmacokinetics,
M G Svaland, and F Kolmannskog, and P E Lillevold, and K P Nordal, and L Ressem, and K J Berg
April 1984, Polskie Archiwum Medycyny Wewnetrznej,
M G Svaland, and F Kolmannskog, and P E Lillevold, and K P Nordal, and L Ressem, and K J Berg
January 1983, European journal of drug metabolism and pharmacokinetics,
M G Svaland, and F Kolmannskog, and P E Lillevold, and K P Nordal, and L Ressem, and K J Berg
April 2011, British journal of anaesthesia,
M G Svaland, and F Kolmannskog, and P E Lillevold, and K P Nordal, and L Ressem, and K J Berg
January 1984, European journal of clinical pharmacology,
M G Svaland, and F Kolmannskog, and P E Lillevold, and K P Nordal, and L Ressem, and K J Berg
January 1983, European journal of clinical pharmacology,
M G Svaland, and F Kolmannskog, and P E Lillevold, and K P Nordal, and L Ressem, and K J Berg
January 1985, Clinical pharmacokinetics,
M G Svaland, and F Kolmannskog, and P E Lillevold, and K P Nordal, and L Ressem, and K J Berg
January 1981, Scandinavian journal of rheumatology,
M G Svaland, and F Kolmannskog, and P E Lillevold, and K P Nordal, and L Ressem, and K J Berg
January 1996, European journal of clinical pharmacology,
M G Svaland, and F Kolmannskog, and P E Lillevold, and K P Nordal, and L Ressem, and K J Berg
March 1988, Anesthesia and analgesia,
Copied contents to your clipboard!